You are here: Home » News-CM » Companies » News
Business Standard

Cadila Healthcare enters into agreement with Enzychem Lifesciences

Capital Market 

For manufacturing licence and technology transfer for Plasmid DNA Vaccine ZyCoV-D

Cadila Healthcare (CHL), has entered into a manufacturing license and technology transfer agreement for its Plasmid DNA based Covid-19 (ZyCoV-D ) vaccine with Enzychem Lifesciences (KOSDAQ:183490) (Enzychem) of Republic of Korea.

CHL will provide manufacturing license and transfer the Plasmid DNA vaccine technology to Enzychem Lifesciences. Both CHL and Enzychem believe that this partnership will lead to an estimated manufacturing of 80 million or more doses of the Plasmid DNA vaccine in 2022. Under the agreement, Enzychem will manufacture and commercialise the vaccine within its territory under a Zydus trademark and CHL will receive the license fees and royalty payments for the same.

ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by CHL against the Covid-19 virus. The vaccine is administered intradermally using the PharmaJetneedle free applicator, which ensures painless intradermal vaccine delivery.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, November 24 2021. 16:23 IST